Ultrasound Evaluation of the Myometrium Using the MUSA Terminology Comparison With Histology
-
- STATUS
- Recruiting
-
- End date
- Mar 30, 2024
-
- participants needed
- 1500
-
- sponsor
- Universitaire Ziekenhuizen Leuven
Summary
The main objective is to evaluate the diagnostic accuracy of the MUSA terms and definitions, as defined in the paper by Van den Bosch T, Dueholm M, ea. in 2015, to differentiate between different types of myometrial lesions of more than 1 cm. The primary aim is the diagnostic accuracy of the MUSA terms and definitions and the secondary aim the development of a prediction model.
Description
Primary aim: Diagnostic accuracy of the MUSA terms and definitions
Every patient planned for hysterectomy for myometrial pathology (e.g. benign fibroid, benign adenomyoma or malignant uterine sarcoma) will undergo a systematic preoperative ultrasound scan. Around 50 ultrasound characteristics (described in Addendum 1) will be assess as to diagnostic accuracy as predictors (Prospective evaluation of MUSA terms and definitions). Figure 1 shows the different histological endpoint with expected prevalence in our study population and table 1 further differentiate those histological endpoints. The estimation for sarcomas is based on preliminary and unpublished results from an ongoing prospective study led by prof dr Antonia Testa from the Universit Cattolica di Sacro Cuore Largo Agostino Gemelli in Rome showing an incidence of 4.9% for uterine sarcomas amongst women with a myometrial lesion referred to their tertiary center (Antonia Testa, personal communication).
Secondary aim: Development of prediction model
The Secondary aim is to build predictive models to differentiate between benign myometrial lesions (e.g. adenomyosis and fibroid) and malignant myometrial lesion (e.g. uterine sarcoma). Because of the small number of cases with malignant myometrial lesion (expected to be 5% of the study population or around 75 women), we will limit the number of variables to be tested in order to avoid overfitting. Based on current literature, we preselected following characteristics for development of a prediction model:
- Outer contour: regular of irregular
- Echogenicity of uterine lesion: uniform (homogeneous) or non-uniform (mixed)
- Colour score: 1 to 4
- Presence of central necrosis
- Maximal diameter of the lesion (in mm)
- Presence of acoustic shadows
Details
| Condition | Leiomyomas, Sarcoma Uterus, Uterine Fibroids, UTERINE FIBROID |
|---|---|
| Treatment | hysterectomy |
| Clinical Study Identifier | NCT04990076 |
| Sponsor | Universitaire Ziekenhuizen Leuven |
| Last Modified on | 12 August 2021 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer